Prostate cancer, notoriously resistant to immunotherapy due to its immunologically cool nature, triggers two pathways to chill an immune attack after one immunotherapy drug fires up the immune system, researchers at The University of Texas MD Anderson Cancer Center report in Nature Medicine.
Researchers at The University of Texas MD Anderson Cancer Center developed a novel chimeric mouse model to test the combination therapy using immune checkpoint blockades with therapies targeting myeloid-derived suppressor cells (MDSCs).
An advanced form of image-guided radiation therapy, known as intensity modulated proton therapy (IMPT), has shown early promise for the treatment of recurrent lung cancer, according to new research from The University of Texas MD Anderson Cancer Center.
As an institution devoted to eliminating cancer, The University of Texas MD Anderson Cancer Center proudly supports the mission of Kick Butts Day to prevent tobacco use in our nation’s children. Organized by the Campaign for Tobacco-Free Kids (CTFK), Kick Butts Day is a national day of awareness focused on educating and empowering youth to choose tobacco-free lifestyles. Through several evidence-based programs, MD Anderson has committed to educating youth about the dangers of tobacco use and its effects on their future health.
A type of functional brain training known as neurofeedback shows promise in reducing symptoms of chemotherapy-induced nerve damage, or neuropathy, in cancer survivors, according to a study by researchers at The University of Texas MD Anderson Cancer Center. The pilot study, published in the journal Cancer, is the largest, to date, to determine the benefits of neurofeedback in cancer survivors.
A Phase III clinical trial involving 101 centers in 21 countries revealed the monoclonal antibody blinatumomab to be more effective than standard chemotherapy for treatment of advanced acute lymphoblastic leukemia (ALL). Study findings were published in the March 1 online issue of the New England Journal of Medicine.
It’s what’s missing in the tumor genome, not what’s mutated, that thwarts treatment of metastatic melanoma with immune checkpoint blockade drugs, researchers at The University of Texas MD Anderson Cancer Center report in Science Translational Medicine.
Anyone who uses an employee badge to enter a building may understand how a protein called ENL opens new possibilities for treating acute myeloid leukemia (AML), a fast-growing cancer of bone marrow and blood cells and the second most common type of leukemia in children and adults.
Adding two blood-borne proteins associated with cancer cell migration increases the predictive ability of the current biomarker for pancreatic cancer to detect early stage disease, a research team from The University of Texas MD Anderson Cancer Center reports in the Journal of the National Cancer Institute.
Discovery of a dual role played by the enzyme phosphoglycerate kinase 1 (PGK1) may indicate a new therapeutic target for glioblastoma, an often fatal form of brain cancer, according to researchers at The University of Texas MD Anderson Cancer Center.
Melanoma patients’ response to a major form of immunotherapy is associated with the diversity and makeup of trillions of potential allies and enemies found in the digestive tract, researchers at The University of Texas MD Anderson Cancer Center report at the ASCO-Society for Immunotherapy in Cancer meeting in Orlando.
For women with a rare subtype of epithelial ovarian or peritoneum cancer, known as low-grade serous carcinoma (LGSC), hormone maintenance therapy (HMT) may significantly improve survival, according to a new study from researchers at The University of Texas MD Anderson Cancer Center.
Women with early-stage breast cancer who had an intermediate risk recurrence score (RS) from a 21-gene expression assay had similar outcomes, regardless of whether they received chemotherapy, a new study from The University of Texas MD Anderson Cancer finds.
Recognizing a critical need to address disparities in cancer care, The University of Texas MD Anderson Cancer Center has been designated as an ECHO superhub for oncology by the ECHO Institute at the University of New Mexico Health Science Center (UNMHSC). MD Anderson is one of just nine ECHO superhub sites in the world and the first focused on oncology.
A team from The University of Texas MD Anderson Cancer Center describes this week in the journal Nature a series of preclinical experiments using patient-derived tumor xenografts (PDXs) and mouse models that point to potential treatments for patients with a rapidly-progressing and resistant subgroup of tumor cells.
Breast cancer patients with dense breast tissue have almost a two-fold increased risk of developing disease in the contralateral breast, according to new research from The University of Texas MD Anderson Cancer.
The University of Texas MD Anderson Cancer Center returns to Southern California this month with its Making Cancer History® Seminar, 3:30-5:30 p.m. Feb. 20 at the Renaissance Indian Wells Resort and Spa, 44400 Indian Wells Lane.
A new method has been found for identifying therapeutic targets in cancers lacking specific key tumor suppressor genes. The process, which located a genetic site for the most common form of prostate cancer, has potential for developing precision therapy for other cancers, such as breast, brain and colorectal, say researchers at The University of Texas MD Anderson Cancer Center. Study results were published in the Feb. 6 online issue of Nature.
In honor of World Cancer Day on Feb. 4, The University of Texas MD Anderson Cancer Center calls for health care providers, organizations, governments and individuals to unite in the common goal of eliminating cancer. Driven to accelerate progress toward Making Cancer History®, MD Anderson is proud to support this global effort.
The University of Texas MD Anderson Cancer Center and Guardant Health today announced a multi-year partnership designed to accelerate comprehensive liquid biopsy technology into the standard of care in cancer treatment.
Charles Aubrey “Mickey” LeMaistre, M.D., past president of The University of Texas MD Anderson Cancer Center and a pioneering crusader against the harmful effects of tobacco use and catalyst of the field of cancer prevention, died today in Houston. He was 92. LeMaistre came to MD Anderson as president in 1978 after serving seven years as chancellor of The University of Texas System.
Cancer cells often delete genes that normally suppress tumor formation. These deletions also may extend to neighboring genes, an event known as “collateral lethality,” which may create new options for development of therapies for several cancers.
Vescor LLC, a new company focused on discovery and development of autophagy targeted therapeutics for cancer treatment, has been formed by The University of Texas MD Anderson Cancer Center, Deerfield Management and two leading autophagy experts.
As national vaccination rates for the human papillomavirus (HPV) remain low, The University of Texas MD Anderson Cancer Center has again united with the 68 other National Cancer Institute (NCI)-designated cancer centers in issuing a joint statement endorsing the recently revised vaccination recommendations from the Centers for Disease Control and Prevention (CDC).
A new genetic-based model may explain how a common form of early-stage breast cancer known as ductal carcinoma in situ (DCIS) progresses to a more invasive form of cancer say researchers at The University of Texas MD Anderson Cancer Center.
The University of Texas MD Anderson Cancer Center and Affimed N.V., a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced an exclusive strategic clinical development and commercialization collaboration to evaluate Affimed’s TandAb technology in combination with MD Anderson’s natural killer cell (NK) product.
In the first study evaluating patient-reported cosmetic outcomes in a population-based cohort of older women with breast cancer, The University of Texas MD Anderson Cancer Center researchers found that less radiation was associated with improved cosmetic satisfaction long-term.
In a pilot study conducted at The University of Texas MD Anderson Cancer Center, image-guided biopsies identified select breast cancer patients who achieved pathologic complete response (pCR) after chemotherapy and/or targeted therapy, neoadjuvant systemic therapy (NST).
The immunotherapy drug nivolumab in combination with standard chemotherapy more than doubled response rates and improved overall survival in patients with acute myeloid leukemia (AML), according to preliminary findings by researchers at The University of Texas MD Anderson Cancer Center.
Richard Gorlick, M.D., an internationally recognized expert in pediatric oncology and hematology, today joined The University of Texas MD Anderson Children’s Cancer Hospital as the division head and department chair of Pediatrics.
Patients who potentially could benefit most from participation in clinical trials due to poor prognoses often are not included based on eligibility criteria, such as existing medical illnesses.
Patients successfully treated for breast, colon and other cancers can go on to develop an often-fatal form of leukemia, sometimes years after completion of treatment, due to a genetic mutation leading to secondary malignancies known as therapy-related myeloid neoplasms (t-MNs).
A cellular component known as the Golgi apparatus may play a role in how lung cancer metastasizes, according to researchers at The University of Texas MD Anderson Cancer Center whose findings were reported in the Nov. 21 online issue of the Journal of Clinical Investigation.
In recognition of wide-ranging contributions to the fields of cancer prevention, patient care, and basic, translational, and clinical research, seven faculty members from The University of Texas MD Anderson Cancer Center have been named Fellows of the American Association for the Advancement of Science (AAAS).
Glioblastoma multiforme remains the most common and highly lethal brain cancer and is known for its ability to relapse.
Astronauts survive in space by wearing high-tech space suits. But how do brain cancer cells thrive when they migrate to inhospitable sites within the brain?
When female employees of a mystery shopping firm called posing as 17-year-olds interested in tanning, 81 percent of indoor tanning facilities complied with the Texas ban on indoor tanning for those under the age of 18 in a study conducted by The University of Texas MD Anderson Cancer Center.
Since 1941, when the Texas Legislature established the state’s first cancer hospital, The University of Texas MD Anderson Cancer Center has been a beacon of hope for more than 1.1 million patients.
Researchers at The University of Texas MD Anderson Cancer Center have developed a new personalized assessment tool that could better predict lung cancer risk in never, light and heavy smokers using a large Taiwanese prospective cohort study.
The University of Texas MD Anderson Cancer Center’s Institute for Applied Cancer Science (IACS) has initiated the first clinical study of a novel drug designed to starve cancer cells, IACS-10759.
Tonya Edwards, a clinical nurse in Palliative Care at The University of Texas MD Anderson Cancer Center, is the recipient of the 2016 Brown Foundation Award for Excellence in Oncology Nursing.
The University of Texas MD Anderson Cancer Center and the Houston Independent School District (HISD) have reached a first-of-its-kind agreement to provide access to an evidence-based, youth-oriented tobacco prevention and cessation program for all 110,000 HISD middle and high school students.
Costs associated with different breast cancer chemotherapy regimens can vary significantly, regardless of effectiveness, according to new research from The University of Texas MD Anderson Cancer Center. Understanding cost differences can help guide informed discussions between patients and physicians when considering chemotherapy options.
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, ribociclib, in combination with the aromatase inhibitor letrozole, dramatically improved progression-free survival (PFS) of post-menopausal women with hormone receptor-positive metastatic breast cancer, compared to the hormone therapy alone.
All 13 newly diagnosed breast cancer patients with BRCA mutations had their tumors shrink significantly when treated with a PARP inhibitor ahead of frontline presurgical chemotherapy in a pilot study at The University of Texas MD Anderson Cancer Center.
In a review of guideline-concordant treatment modalities for women with early stage breast cancer, mastectomy and reconstruction had the highest rate of complications and complication-related costs, regardless of age.
Adaptimmune Therapeutics and The University of Texas MD Anderson Cancer Center announced today they have entered into a multi-year strategic alliance designed to expedite the development of novel adoptive T-cell therapies for multiple types of cancer.
Melanoma tumors use genetic mutations in a prominent immune response pathway to resist the immunotherapy ipilimumab, researchers from The University of Texas MD Anderson Cancer Center report in the journal Cell.
The University of Texas MD Anderson Cancer Center is pleased to welcome Vice President Joe Biden to Houston and the historic site where 54 years ago President John F. Kennedy delivered his speech about going to the moon, which inspired generations to lead our nation in innovation and space exploration.
The University of Texas MD Anderson Cancer Center was awarded $19 million this week from the Cancer Prevention and Research Institute of Texas (CPRIT) for the recruitment of four cancer scientists and research facility funding.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right